Another PML case associated with Raptiva
Executive Summary
A second case of progressive multifocal leukoencephalopathy associated with Raptiva (efalizumab) prompts Genentech to issue another Dear Healthcare Provider letter to dermatologists and neurologists. The current case caused the death of a 73-year old woman treated for four years with Raptiva for chronic plaque psoriasis, and follows a similar case in October. Genentech says it believes the drug likely increases the risk of PML and that prolonged exposure to Raptiva and older age may further increase this risk. The drug's labeling was updated in October and FDA has asked the firm to submit a Risk Evaluation and Mitigation Strategy (1"The Pink Sheet" DAILY, Oct. 17, 2008)
You may also be interested in...
Raptiva PML Case Brings Another REMS
FDA wants black-box warning, new safety plan for psoriasis drug.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.